> Austria's Intercell says a Phase III safety study of its Japanese Encephalitis virus vaccine--which is scheduled for a 2007 launch--showed no adverse effects. The vaccine will be marketed by Intercell partner Novartis. Report
> Carl Icahn and three associates will go on the board of ImClone systems as part of a deal to avoid a proxy fight. Report
> Denmark's NeuroSearch has inked a deal to buy Sweden's Carlsson Research for 875M skr. Carlsson has been developing drugs for the central nervous system. Report
> As planned, Canada's Inex Pharmaceuticals has filed to spin out assets into Tekmira Pharmaceuticals. "We are confident that Tekmira will become a company with all the attributes necessary to take INEX's promising oligonucleotide-based products forward into clinical trials, to work with and benefit from the product development achievements of INEX's existing partners and to build significant value for shareholders," said Inex CEO Timothy Ruane. Release
> In another legal gambit to protect itself from a generic version of Wellbutrin XL, Biovail has sued the FDA saying it can't approve a generic without addressing a citizen's petition first. Report
And Finally... One couple's quest to gain insurance coverage for their child's rare genetic disorder included an Internet campaign aimed at Aetna. Article